Wang Haipeng, Sun Qiang, Vitry Agnes, Nguyen Tuan Anh
1 School of Health Care Management, Key Lab of Health Economics and Policy Research, NHFPC, Shandong University, Jinan, Shandong, China.
2 The Centre for Economic Research, Shandong University, Jinan, Shandong, China.
Asia Pac J Public Health. 2017 May;29(4):268-277. doi: 10.1177/1010539517700472. Epub 2017 Apr 11.
Access to affordable essential medicines for noncommunicable, chronic diseases is critical in management of the diseases. This study aims to assess the availability, prices, and affordability of medicines for common chronic diseases in the Asia Pacific Region (APR). A secondary analysis of medicines price and availability data from the Health Action International's (HAI) database was undertaken using the standardized WHO/HAI methodology. The median availability of any medicine in the public sector was 35.5% compared with 56.7% in the private sector. Countries paid 1.4 times the International Reference Price to procure lowest-priced generics (LPGs) and 9.1 times for innovator brands (IBs). Patients would have to spend 2.3 and 0.4 day's wages to purchase one month's treatment of a chronic disease for IBs and LPGs, respectively in the private sector. These findings highlight the need to increase availability, reduce prices, and improve affordability of the medicines.
获得用于非传染性慢性病的可负担得起的基本药物对于这些疾病的管理至关重要。本研究旨在评估亚太地区常见慢性病药物的可获得性、价格和可负担性。使用世界卫生组织/国际卫生行动组织（WHO/HAI）的标准化方法，对来自国际卫生行动组织（HAI）数据库的药品价格和可获得性数据进行了二次分析。公共部门中任何药物的中位可获得性为35.5%，而私营部门为56.7%。各国采购最低价仿制药（LPG）的价格是国际参考价格的1.4倍，采购创新品牌药（IB）的价格是国际参考价格的9.1倍。在私营部门，患者分别需要花费2.3天和0.4天的工资来购买一个月治疗慢性病的创新品牌药和最低价仿制药。这些发现凸显了提高药物可获得性、降低价格以及改善药物可负担性的必要性。
